Kugler et al. created a dual targeting scFv triplebody specific for Interleukin-3 receptor α chain (CD123), CD33 and CD16 showing responses against acute myeloid leukemia (AML)-cell lines [8]. This evidence concerns the gene CD33 and acute myeloid leukemia.